Non-Hodgkins Lymphoma Treatment Market Foresees Skyrocketing Growth By 2026 by Global Top Players - Novartis International, Pharmacyclics, Bayer, F. Hoffmann LA Roche, Amgen, Eli Lilly, Nordic Nanovector, AbbVie

Global Non-Hodgkins Lymphoma Treatment Market 2018 report includes extensive Market analysis and industry landscape along with SWOT analysis and PESTEL analysis of the important vendors. The analysis is conducted with a blend of secondary and primary advice for inputs from participants in the industry. Non-Hodgkins Lymphoma Treatment industry report covers the prospects of Women’S Health Products in the forecast period of 2018-2026 and the scenario.

North America holds the major share in the market because of the high incidence rate of blood cancers in the U.S. According to Leukemia and Lymphoma Society, non-Hodgkin lymphoma is the seventh most common cancer in the U.S. and fifth in the UK. The National Cancer Institute estimated 72,580 new cases and 20,150 deaths in 2016 due to NHL in the U.S. According to the American Cancer Society, 20 cases of NHL, 6 cases of myeloma and 13 cases of leukemia were estimated per 100,000 population in 2014 in the U.S. Moreover, the organization states that, around 6 out of 10 people diagnosed with non-Hodgkin lymphoma are aged 65 and above. Also, NHL is much more common in men than in women.

Get Sample Copy of Research on Human Microbiome Market, Click – https://www.coherentmarketinsights.com/insight/request-sample/547

Non-Hodgkins Lymphoma (NHL) is a type of cancer that occurs due to abnormal functioning of B or T lymphocytes and leukocytes. Around 80% of the lymphomas arise in developing B cells and the remainder arise in developing T cells. This generally occurs in bone marrow, lymph nodes, spleen, blood and other organs that are part of lymphatic system. The patients suffering from non-Hodgkin’s lymphoma are observed with symptoms like fever, weight loss, swelling of lymph nodes, anorexia, fatigue and dyspnoea. Treatment of the NHL depends whether the cells are fast or slow growing and also whether it is spread in one area or different areas of the body. Treatment options for NHL include immunotherapy, chemotherapy, stem cell transplantation, targeted therapy, monoclonal antibody therapy and radiation therapy. If blood thickens in the patient due to presence of antibodies then plasmapheresis can also be carried out. Various products available for treating lymphoma include Deltasone, Adcertis, Folotyn, Adriamycin, Prednicot, Leukeran, Velcade, Thioplex and Decadron.

The launch of new drugs in the near future expected to support the growth of non-hodgkins lymphoma treatment market. For instance, a new drug Axicabtagene ciloleucel, received priority review status to get commercialize for the treatment of non-hodgkins lymphoma as a second line therapy. This drug is expected to launch in later of year 2017.

Some cellular therapies such as T cell therapy and CAR T cell therapy are also being developed where patient’s own T cells are used to attack non-Hodgkin's lymphoma cells. Also various small molecule targeted therapies such as idelalisib and ibrutinib are latest advancements for the treatment of NHL.

Ask For Discount on Human Microbiome Market Report, Click – https://www.coherentmarketinsights.com/insight/request-discount/547

Non-Hodgkins Lymphoma Treatment Market Taxonomy -

On the basis of type of non-hodgkins lymphoma, the non-hodgkins lymphoma treatment market is classified into -
- B-cell lymphoma
- T-cell lymphoma

On the basis of end user, the non-hodgkins lymphoma treatment market is classified into -
- Hospitals
- Clinics

Rituxan drug which is used to treat NHL and had been a front-line treatment regimen, though there has been an increasing rituximab resistance. To overcome this resistance, there has been various R&D practices that will create space in the market. For instance, Roche, Inc. is conducting phase IIIstudy of Gazyva/Gazyvaro in people with previously untreated with diffuse large B-cell lymphoma. . The extension of already marketed drugs such as Velcade as a front-line therapy for mantle cell lymphoma (MCL), Revlimid for maintenance therapy of diffuse large B-cell lymphoma (DLBCL) and Adcetris for CD30 T-cell lymphoma would be further contributing towards the non-hodgkins lymphoma treatment market growth. In 2016, the U.S. Government allocated US$ 5.2 billion to the National Cancer Institute (NCI) for cancer research and training purpose.

Key players in the non-Hodgkin’s lymphoma treatment market inlcude Novartis International AG, Pharmacyclics, Inc., Bayer AG, F. Hoffmann LA Roche, Amgen, Inc., Eli Lilly and Company, Nordic Nanovector A/S and AbbVie, Inc. The prominent players are undertaking collaborative strategies for clinical research to yield new drugs which will aid them to gain competitive advantage.

Else place an Inquire before Purchase “Global Non-Hodgkins Lymphoma Treatment Market Size, Status and Forecast Report 2026": https://www.coherentmarketinsights.com/insight/talk-to-analyst/547

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702

Non-Hodgkins Lymphoma Treatment Market Foresees Skyrocketing Growth By 2026 by Global Top Players - Novartis International, Pharmacyclics, Bayer, F. Hoffmann LA Roche, Amgen, Eli Lilly, Nordic Nanovector, AbbVie Non-Hodgkins Lymphoma Treatment Market Foresees Skyrocketing Growth By 2026 by Global Top Players - Novartis International, Pharmacyclics, Bayer, F. Hoffmann LA Roche, Amgen, Eli Lilly, Nordic Nanovector, AbbVie Reviewed by Sagar Jagtap on 08:41 Rating: 5

No comments:

Powered by Blogger.